Showing results (51-60 of 182) with videos related to
Sort By:
Pageof 19
Oncology (Williston Park, N.Y.)|May 16, 2022
Current Treatment of Peripheral T-cell LymphomaRobert Stuver, Zachary D Epstein-Peterson, William T Johnson, et al.Blood Advances|July 11, 2022
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysisNazila Shafagati, Min J Koh, Leora Boussi, et al.Clinical Lymphoma, Myeloma & Leukemia|October 31, 2012
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experienceMartin H Voss, Matthew A Lunning, Jocelyn C Maragulia, et al.European Journal of Haematology|March 27, 2023
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposureMichael J Buege, Esther Drill, Steven M Horwitz, et al.The Breast Journal|December 7, 2018
Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer centerBrittany Z Dashevsky, Katherine M Gallagher, Anne Grabenstetter, et al.Journal of the American Academy of Dermatology|December 3, 2014
Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective studyMichael A Marchetti, Melissa P Pulitzer, Patricia L Myskowski, et al.Cytometry. Part B, Clinical Cytometry|April 22, 2022
PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood in mycosis fungoides/Sezary syndromeNatasha E Lewis, Qi Gao, Kseniya Petrova-Drus, et al.Blood Advances|April 20, 2018
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphomaAnita Kumar, Santosha Vardhana, Alison J Moskowitz, et al.Blood|February 15, 2003
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBradley C Ekstrand, Jennifer B Lucas, Steven M Horwitz, et al.Blood|March 22, 2014
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M Horwitz, Ranjana H Advani, Nancy L Bartlett, et al.Pageof 19